Financiado en parte por Pfizer, GlaxoSmithKline, Novartis Pharmaceuticals Corporation
Dietary magnesium intake and fracture risk: data from a large prospective study
Veronese N, Stubbs B, Solmi M, Noale M, Vaona A, Demurtas J, Maggi S
The British journal of nutrition · 48 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Foundation for the National Institutes of Health
- Gobierno
- U.S. Department of Health and Human Services
- Empresa
- Pfizer
- Empresa
- GlaxoSmithKline
- Empresa
- Novartis Pharmaceuticals Corporation
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Gobierno
- NIAMS NIH HHS
- Subvenciones
- U.S. Department of Health and Human Services (N01-AR-2-2258); U.S. Department of Health and Human Services (N01-AR-2-2261); U.S. Department of Health and Human Services (N01-AR-2-2262); Pfizer (N01-AR-2-2258); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022262); Pfizer (N01-AR-2-2259); GlaxoSmithKline (N01‐AR‐2‐2261); Foundation for the National Institutes of Health ((N01-AR-2-2258); National Institutes of Health (N01 AR‐2‐2260); National Institutes of Health (N01-AR-2-2258,N01-AR-2-2259,N01-AR-2-2260,N01-AR-2-2261,N01-AR-2-2262); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022260); Novartis Pharmaceuticals Corporation (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2262); GlaxoSmithKline (N01-AR-2-2258); GlaxoSmithKline (N01-AR-2-2260); National Institutes of Health (N01-AR-2-2258); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022261); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022259); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022258); GlaxoSmithKline (N01-AR-2-2259); Pfizer (N01-AR-2-2260); Novartis Pharmaceuticals Corporation (N01-AR-2-2260); U.S. Department of Health and Human Services (N01-AR-2-2259); National Institutes of Health (N01‐AR‐2‐2259); U.S. Department of Health and Human Services (N01-AR-2-2260); National Institutes of Health (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2258); Pfizer (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2259); Pfizer (N01-AR-2-2262); GlaxoSmithKline (N01-AR-2-2262); National Institutes of Health (N01-AR-2-2262)
Según 8 financiadores declarados.
Publicación
- Publicado
- 2017-06-14 · Br J Nutr · vol. 117 · número 11 · págs. 1570–1576
- Editorial
- Cambridge University Press
- Citado
- 69 citas · más que el 95% de estudios similares · 4.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 38 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Magnesium in Health and Disease · Bone health and osteoporosis research · Bone Metabolism and Diseases
- Palabras clave
- Medicine, Osteoarthritis, Osteoporosis, Confounding, Hazard ratio, Prospective cohort study, Cohort study, Lower risk, Cohort, Internal medicine, Confidence interval
- MeSH
- humans, osteoporosis, osteoarthritis, knee, magnesium, micronutrients, diet, diet surveys, nutrition assessment, incidence, proportional hazards models, risk factors, follow-up studies, prospective studies, sex factors, dietary supplements, aged, middle aged, female, male, osteoporotic fractures
7 autores
- Nicola Veronese🇮🇹 · autor de correspondenciaNeuroscience Institute; National Research Council
- Brendon Stubbs🇬🇧King's College London; South London and Maudsley NHS Foundation Trust
- Marco Solmi🇮🇹University of Padua
- Marianna Noale🇮🇹Neuroscience Institute; National Research Council
- Alberto Vaona🇮🇹University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
- Jacopo Demurtas🇮🇹Azienda Usl Toscana Centro
- Stefania Maggi🇮🇹Neuroscience Institute; National Research Council
Resumen
El texto original del estudio, en el idioma en que se publicó.
Research considering the relationship between dietary Mg and osteoporosis as well as fractures are sparse and conflicting. We therefore aimed to investigate Mg intake and the onset of fractures in a large cohort of American men and women involved in the Osteoarthritis Initiative over a follow-up period of 8 years. Dietary Mg intake (including that derived from supplementation) was evaluated through a FFQ at baseline and categorised using sex-specific quintiles (Q); osteoporotic fractures were evaluated through self-reported history. Overall, 3765 participants (1577 men; 2071 women) with a mean age of 60·6 (sd 9·1) years were included. During follow-up, 560 individuals (198 men and 368 women) developed a new fracture. After adjusting for fourteen potential confounders at baseline and taking those with lower Mg intake as reference (Q1), men (hazard ratio (HR) 0·47; 95 % CI 0·21, 1·00, P=0·05) and women (HR 0·38; 95 % CI 0·17, 0·82, P=0·01) in the highest quintile reported a significantly lower risk for fracture. Women meeting the recommended Mg intake were at a 27 % decreased risk for future fractures. In conclusion, higher dietary Mg intake has a protective effect on future osteoporotic fractures, especially in women with a high risk for knee osteoarthritis. Those women meeting the recommended Mg intake appear to be at a lower risk for fractures.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.